$DNPUF Multiple Myeloma (Kahler Disease) Ther
Post# of 273254
Posted On: 09/25/2016 9:15:52 AM
$DNPUF
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.27 (-0.03), DRNA: 4.23 (-0.07), INCY: 88.98 (-0.29), LLY: 81.16 (-0.13), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ANTH: 3.19 (+0.05), EXEL: 14.89 (+0.15)
World Thymus Cancer Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/chmdh8/thymus_cancer) has announced the addition of the "Thymus Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thymus Cancer Overview - Therapeutics Development - Pipeline Products for Thymus Cancer - Overview - Pipeline Products for Thymus Cancer - Comparative Analysis - Thymus Cancer - Therapeutics under Development by Companies - Thymus Cancer - Therapeutics under Investigation by Universities/Institutes - Thymus Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thymus Cancer - Products under Development by Companies - Thymus Cancer - Products under Investigation by Universities/Institutes - Thymus Cancer - Companies Involved in Therapeutics Development - Cellceutix Corporation - Merck & Co., Inc. - Novartis AG - Onxeo SA - Sumitomo Dainippon Pharma Co., Ltd. - Tiziana Life Sciences Plc For more information visit http://www.researchandmarkets.com/research/ch...mus_cancer
MRK: 62.96 (-0.06), NVS: 81.48 (-0.55)
Klebsiella Pneumoniae Infections Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdwshp/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Klebsiella Pneumoniae Infections Overview - Therapeutics Development - Pipeline Products for Klebsiella Pneumoniae Infections - Overview - Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis - Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies - Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Klebsiella Pneumoniae Infections - Products under Development by Companies - Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Boehringer Ingelheim GmbH - Cellceutix Corporation - Debiopharm International S.A. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/xdwshp/klebsiella
TTPH: 3.83 (-0.04), SRPT: 57.83 (-3.14), PFE: 34.26 (+0.11), MRK: 62.96 (-0.06)
Global Soft Tissue Sarcoma Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/thz6jx/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Soft Tissue Sarcoma Overview - Therapeutics Development - Pipeline Products for Soft Tissue Sarcoma - Overview - Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis - Soft Tissue Sarcoma - Therapeutics under Development by Companies - Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Soft Tissue Sarcoma - Products under Development by Companies - Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Amgen Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - CASI Pharmaceuticals Inc. - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Double Bond Pharmaceutical International AB - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gem Pharmaceuticals, LLC - GlaxoSmithKline Plc - Lytix Biopharma AS - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Noxxon Pharma AG - OncoTherapy Science, Inc. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Philogen S.p.A. - Plexxikon Inc. - Siena Biotech S.p.A. - Sigma-Tau S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. - Targovax AS For more information visit http://www.researchandmarkets.com/research/th...oft_tissue
CLRB: 2.74 (-0.04), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), EPZM: 9.70 (-0.04), GSK: 43.42 (-0.16), CASI: 1.19 (+0.06), MACK: 5.98 (-0.16), MRK: 62.96 (-0.06), CYTR: 0.57 (-0.01), NVS: 81.48 (-0.55), CELGZ: 1.24 (+0.04), EXEL: 14.89 (+0.15)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 118.81 (-0.65), NBIX: 53.94 (-0.22), KMPH: 4.56 (+0.01), ZGNX: 10.45 (+0.93), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), TEVA: 51.47 (+0.24), ITCI: 42.40 (+1.53), OMER: 11.64 (-0.26)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 174.80 (-0.82), ATRA: 20.12 (-0.34), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ATNM: 1.79 (+0.03), SNDX: 13.30 (-0.35), BLCM: 20.57 (+1.26), BPTH: 1.39 (-0.05), TEVA: 51.47 (+0.24), AGIO: 53.03 (unch), XLRN: 39.50 (-0.50), ARRY: 3.65 (-0.04)
World Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/w7bf8s/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview - Therapeutics Development - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - ContraFect Corporation - Debiopharm International S.A. - ImmuVen, Inc. - Lytix Biopharma AS - PharmaIN Corporation - Sealife PHARMA GMBH - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/w7...llinsuscep
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 34.26 (+0.11), VBAY: (), BMY: 56.48 (+0.06), LPTN: 3.89 (+0.29), OMER: 11.64 (-0.26), CUR: 0.32 (+0.01), CELGZ: 1.24 (+0.04)
Streptococcus Pneumoniae Infection Therapeutic Developments Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/klpqfj/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Streptococcus Pneumoniae Infection Overview - Therapeutics Development - Pipeline Products for Streptococcus Pneumoniae Infection - Overview - Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis - Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Streptococcus Pneumoniae Infection - Products under Development by Companies - Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development - Abera Bioscience AB - Allergan Plc - Alvogen Korea - Arsanis Biosciences GmbH - AstraZeneca Plc - Beijing Minhai Biotechnology Co., Ltd - ContraFect Corporation - Daiichi Sankyo Company, Limited - Eurocine Vaccines AB - FluGen, Inc. - GlaxoSmithKline Plc - ImmunoBiology Limited - Lascco SA - Liquidia Technologies, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Mucosis B.V. - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Valneva SE - Vaxxilon AG - Virometix AG - Walvax Biotechnology Co., Ltd. - Wellstat Vaccines, LLC - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/kl...eptococcus
AGN: 243.94 (+0.51), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), GSK: 43.42 (-0.16), SVA: 5.81 (-0.06)
Irritable Bowel Syndrome - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2k9l4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identifies emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develops strategic initiatives by understanding the focus areas of leading companies - To identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome - To plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4D Pharma Plc - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allergan Plc - Ardelyx, Inc. - Astellas Pharma Inc. - CJ HealthCare Corp. - Dong-A Socio Group - Enterome Bioscience SA - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - SK Biopharmaceuticals Co., Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/n2...able_bowel
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), SYN: 1.75 (-0.02), IRWD: 15.72 (-0.15), PFE: 34.26 (+0.11)
Enterococcus Faecium Infections - Global Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzzqvp/enterococcus) has announced the addition of the "Enterococcus faecium Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Enterococcus Faecium Infections Overview - Therapeutics Development - Pipeline Products for Enterococcus Faecium Infections - Overview - Pipeline Products for Enterococcus Faecium Infections - Comparative Analysis - Enterococcus Faecium Infections - Therapeutics under Development by Companies - Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Enterococcus Faecium Infections - Products under Development by Companies - Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen Korea - Aphios Corporation - BioSource Pharm, Inc. - Cellceutix Corporation - ContraFect Corporation - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rz...terococcus
OGEN: 0.53 (-0.02)
World Psychosis Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/255wj4/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Psychosis Overview - Therapeutics Development - Pipeline Products for Psychosis - Overview - Pipeline Products for Psychosis - Comparative Analysis - Psychosis - Therapeutics under Development by Companies - Psychosis - Therapeutics under Investigation by Universities/Institutes - Psychosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psychosis - Products under Development by Companies - Psychosis - Products under Investigation by Universities/Institutes - Psychosis - Companies Involved in Therapeutics Development - Acadia Pharmaceuticals Inc. - Addex Therapeutics Ltd - Eli Lilly and Company - Evotec AG - Gabather AB - Glenmark Pharmaceuticals Ltd. - Heptares Therapeutics Limited - Integrative Research Laboratories Sweden AB - Newron Pharmaceuticals S.p.A. - Reviva Pharmaceuticals Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/255wj4/psychosis
ACAD: 34.98 (unch), LLY: 81.16 (-0.13)
Lewy body Dementia Pipeline Review, H2 2015 - Analysis, Technologies, Trends & Forecasts
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/r7q53h/lewy_body) has announced the addition of the "Lewy body Dementia - Pipeline Review, H2 2015" report to their offering. The report Lewy body Dementia - Pipeline Review, H2 2015', provides an overview of the Lewy body Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Scope: - The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lewy body Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lewy body Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics Companies Mentioned: - Addex Therapeutics Ltd - Axovant Sciences Ltd. - BioArctic Neuroscience AB - Neuropore Therapies, Inc. - ProteoTech, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/r7q53h/lewy_body
AXON: 15.28 (+0.14)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 7.96 (-0.17), NWBO: 0.53 (-0.02)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), GSK: 43.42 (-0.16), ALKS: 49.58 (-1.42), AGN: 243.94 (+0.51), JNJ: 118.81 (-0.65), ITCI: 42.40 (+1.53), CUR: 0.32 (+0.01)
Sumitomo Dainippon Pharma Co., Ltd. Industry - Global Product Pipeline Review - 2015
M2 - Wed Dec 16, 4:35AM CST
Summary
Sunovion Celebrates Five-Year Anniversary Milestone
BusinessWire - Thu Oct 15, 9:00AM CDT
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion's parent company Sumitomo Dainippon Pharma Co., Ltd. Over the course of five years, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.
Streptococcus Pyogenes Infections Pipeline Review, H2 2015 - 6 Companies & 10 Drug Profiles
M2 - Mon Oct 05, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxmsnq/streptococcus) has announced the addition of the "Streptococcus Pyogenes Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Aureogen Biosciences, Inc. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Wellstat Vaccines, LLC Drug Profiles - BMY-28117 - HB-1345 - SM-295291 - SM-369926 - Small Molecules to Inhibit DHFR for Infectious Diseases - Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - streptococcus [serotype A] vaccine - streptococcus polysaccharide [serotype A] vaccine - streptococcus pyogenes vaccine - streptococcus pyogenes vaccine (30-valent) For more information visit http://www.researchandmarkets.com/research/px...eptococcus
GSK: 43.42 (-0.16)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 243.94 (+0.51), VRTX: 90.63 (-1.49), SRPT: 57.83 (-3.14), GSK: 43.42 (-0.16)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 81.48 (-0.55)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.27 (-0.03), DRNA: 4.23 (-0.07), INCY: 88.98 (-0.29), LLY: 81.16 (-0.13), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ANTH: 3.19 (+0.05), EXEL: 14.89 (+0.15)
World Thymus Cancer Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/chmdh8/thymus_cancer) has announced the addition of the "Thymus Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thymus Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thymus Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Thymus Cancer Overview - Therapeutics Development - Pipeline Products for Thymus Cancer - Overview - Pipeline Products for Thymus Cancer - Comparative Analysis - Thymus Cancer - Therapeutics under Development by Companies - Thymus Cancer - Therapeutics under Investigation by Universities/Institutes - Thymus Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Thymus Cancer - Products under Development by Companies - Thymus Cancer - Products under Investigation by Universities/Institutes - Thymus Cancer - Companies Involved in Therapeutics Development - Cellceutix Corporation - Merck & Co., Inc. - Novartis AG - Onxeo SA - Sumitomo Dainippon Pharma Co., Ltd. - Tiziana Life Sciences Plc For more information visit http://www.researchandmarkets.com/research/ch...mus_cancer
MRK: 62.96 (-0.06), NVS: 81.48 (-0.55)
Klebsiella Pneumoniae Infections Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 02, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdwshp/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Klebsiella Pneumoniae Infections Overview - Therapeutics Development - Pipeline Products for Klebsiella Pneumoniae Infections - Overview - Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis - Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies - Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Klebsiella Pneumoniae Infections - Products under Development by Companies - Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes - Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Boehringer Ingelheim GmbH - Cellceutix Corporation - Debiopharm International S.A. - Evaxion Biotech - F. Hoffmann-La Roche Ltd. - FOB Synthesis, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - MicuRx Pharmaceuticals, Inc. - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/xdwshp/klebsiella
TTPH: 3.83 (-0.04), SRPT: 57.83 (-3.14), PFE: 34.26 (+0.11), MRK: 62.96 (-0.06)
Global Soft Tissue Sarcoma Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/thz6jx/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Soft Tissue Sarcoma Overview - Therapeutics Development - Pipeline Products for Soft Tissue Sarcoma - Overview - Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis - Soft Tissue Sarcoma - Therapeutics under Development by Companies - Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Soft Tissue Sarcoma - Products under Development by Companies - Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes - Soft Tissue Sarcoma - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Amgen Inc. - Arog Pharmaceuticals, Inc. - Bayer AG - CASI Pharmaceuticals Inc. - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Double Bond Pharmaceutical International AB - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gem Pharmaceuticals, LLC - GlaxoSmithKline Plc - Lytix Biopharma AS - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Noxxon Pharma AG - OncoTherapy Science, Inc. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Philogen S.p.A. - Plexxikon Inc. - Siena Biotech S.p.A. - Sigma-Tau S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. - Targovax AS For more information visit http://www.researchandmarkets.com/research/th...oft_tissue
CLRB: 2.74 (-0.04), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), EPZM: 9.70 (-0.04), GSK: 43.42 (-0.16), CASI: 1.19 (+0.06), MACK: 5.98 (-0.16), MRK: 62.96 (-0.06), CYTR: 0.57 (-0.01), NVS: 81.48 (-0.55), CELGZ: 1.24 (+0.04), EXEL: 14.89 (+0.15)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 118.81 (-0.65), NBIX: 53.94 (-0.22), KMPH: 4.56 (+0.01), ZGNX: 10.45 (+0.93), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), TEVA: 51.47 (+0.24), ITCI: 42.40 (+1.53), OMER: 11.64 (-0.26)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 174.80 (-0.82), ATRA: 20.12 (-0.34), STML: 10.58 (+0.35), SNTA: 0.34 (+0.07), ATNM: 1.79 (+0.03), SNDX: 13.30 (-0.35), BLCM: 20.57 (+1.26), BPTH: 1.39 (-0.05), TEVA: 51.47 (+0.24), AGIO: 53.03 (unch), XLRN: 39.50 (-0.50), ARRY: 3.65 (-0.04)
World Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/w7bf8s/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Overview - Therapeutics Development - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Overview - Pipeline Products for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Development by Companies - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Products under Investigation by Universities/Institutes - Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - ContraFect Corporation - Debiopharm International S.A. - ImmuVen, Inc. - Lytix Biopharma AS - PharmaIN Corporation - Sealife PHARMA GMBH - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/w7...llinsuscep
Diabetic Neuropathy Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/hz8k3l/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diabetic Neuropathy Overview - Therapeutics Development - Pipeline Products for Diabetic Neuropathy - Overview - Pipeline Products for Diabetic Neuropathy - Comparative Analysis - Diabetic Neuropathy - Therapeutics under Development by Companies - Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes - Diabetic Neuropathy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diabetic Neuropathy - Products under Development by Companies - Diabetic Neuropathy - Products under Investigation by Universities/Institutes - Diabetic Neuropathy - Companies Involved in Therapeutics Development - Araim Pharmaceuticals Inc. - Bristol-Myers Squibb Company - Cebix Incorporated - Celgene Corporation - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - NovaLead Pharma Pvt. Ltd. - Nuvo Research Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Reata Pharmaceuticals, Inc. - Relief Therapeutics S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hz8k3l/diabetic
PFE: 34.26 (+0.11), VBAY: (), BMY: 56.48 (+0.06), LPTN: 3.89 (+0.29), OMER: 11.64 (-0.26), CUR: 0.32 (+0.01), CELGZ: 1.24 (+0.04)
Streptococcus Pneumoniae Infection Therapeutic Developments Pipeline Review, H2 2015
M2 - Thu Jan 28, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/klpqfj/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Streptococcus Pneumoniae Infection Overview - Therapeutics Development - Pipeline Products for Streptococcus Pneumoniae Infection - Overview - Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis - Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Streptococcus Pneumoniae Infection - Products under Development by Companies - Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes - Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development - Abera Bioscience AB - Allergan Plc - Alvogen Korea - Arsanis Biosciences GmbH - AstraZeneca Plc - Beijing Minhai Biotechnology Co., Ltd - ContraFect Corporation - Daiichi Sankyo Company, Limited - Eurocine Vaccines AB - FluGen, Inc. - GlaxoSmithKline Plc - ImmunoBiology Limited - Lascco SA - Liquidia Technologies, Inc. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Mucosis B.V. - Panacea Biotec Limited - Prometheon Pharma, LLC - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Valneva SE - Vaxxilon AG - Virometix AG - Walvax Biotechnology Co., Ltd. - Wellstat Vaccines, LLC - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/kl...eptococcus
AGN: 243.94 (+0.51), MRK: 62.96 (-0.06), AZN: 33.97 (-0.31), GSK: 43.42 (-0.16), SVA: 5.81 (-0.06)
Irritable Bowel Syndrome - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2k9l4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identifies emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develops strategic initiatives by understanding the focus areas of leading companies - To identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome - To plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4D Pharma Plc - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allergan Plc - Ardelyx, Inc. - Astellas Pharma Inc. - CJ HealthCare Corp. - Dong-A Socio Group - Enterome Bioscience SA - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - SK Biopharmaceuticals Co., Ltd. - SK Chemicals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/n2...able_bowel
SGYP: 5.61 (+0.03), AGN: 243.94 (+0.51), SYN: 1.75 (-0.02), IRWD: 15.72 (-0.15), PFE: 34.26 (+0.11)
Enterococcus Faecium Infections - Global Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzzqvp/enterococcus) has announced the addition of the "Enterococcus faecium Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Enterococcus Faecium Infections Overview - Therapeutics Development - Pipeline Products for Enterococcus Faecium Infections - Overview - Pipeline Products for Enterococcus Faecium Infections - Comparative Analysis - Enterococcus Faecium Infections - Therapeutics under Development by Companies - Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Enterococcus Faecium Infections - Products under Development by Companies - Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes - Enterococcus Faecium Infections - Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen Korea - Aphios Corporation - BioSource Pharm, Inc. - Cellceutix Corporation - ContraFect Corporation - Helix BioMedix, Inc. - Hsiri Therapeutics, LLC - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rz...terococcus
OGEN: 0.53 (-0.02)
World Psychosis Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/255wj4/psychosis) has announced the addition of the "Psychosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Psychosis Overview - Therapeutics Development - Pipeline Products for Psychosis - Overview - Pipeline Products for Psychosis - Comparative Analysis - Psychosis - Therapeutics under Development by Companies - Psychosis - Therapeutics under Investigation by Universities/Institutes - Psychosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psychosis - Products under Development by Companies - Psychosis - Products under Investigation by Universities/Institutes - Psychosis - Companies Involved in Therapeutics Development - Acadia Pharmaceuticals Inc. - Addex Therapeutics Ltd - Eli Lilly and Company - Evotec AG - Gabather AB - Glenmark Pharmaceuticals Ltd. - Heptares Therapeutics Limited - Integrative Research Laboratories Sweden AB - Newron Pharmaceuticals S.p.A. - Reviva Pharmaceuticals Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/255wj4/psychosis
ACAD: 34.98 (unch), LLY: 81.16 (-0.13)
Lewy body Dementia Pipeline Review, H2 2015 - Analysis, Technologies, Trends & Forecasts
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/r7q53h/lewy_body) has announced the addition of the "Lewy body Dementia - Pipeline Review, H2 2015" report to their offering. The report Lewy body Dementia - Pipeline Review, H2 2015', provides an overview of the Lewy body Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Scope: - The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lewy body Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lewy body Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics Companies Mentioned: - Addex Therapeutics Ltd - Axovant Sciences Ltd. - BioArctic Neuroscience AB - Neuropore Therapies, Inc. - ProteoTech, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/r7q53h/lewy_body
AXON: 15.28 (+0.14)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 7.96 (-0.17), NWBO: 0.53 (-0.02)
Major Depressive Disorder - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/496zq2/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Major Depressive Disorder's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aequus Pharmaceuticals Inc. - Alkermes Plc - Allergan Plc - Angelini Group - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - e-Therapeutics Plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - H. Lundbeck A/S - Hua Medicine Ltd. - Intra-Cellular Therapies, Inc. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Johnson & Johnson - Lead Discovery Center GmbH - Luye Pharma Group Ltd. - Mapreg S.A.S. - Methylation Sciences Inc. - miCure Therapeutics Ltd. - Mitsubishi Tanabe Pharma Corporation - Naurex, Inc. - Neuralstem, Inc. - nLife Therapeutics, S.L. - Otsuka Holdings Co., Ltd. - Pherin Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. - Sunovion Pharmaceuticals Inc. - Suven Life Sciences Ltd. - VistaGen Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/49...depressive
LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), GSK: 43.42 (-0.16), ALKS: 49.58 (-1.42), AGN: 243.94 (+0.51), JNJ: 118.81 (-0.65), ITCI: 42.40 (+1.53), CUR: 0.32 (+0.01)
Sumitomo Dainippon Pharma Co., Ltd. Industry - Global Product Pipeline Review - 2015
M2 - Wed Dec 16, 4:35AM CST
Summary
Sunovion Celebrates Five-Year Anniversary Milestone
BusinessWire - Thu Oct 15, 9:00AM CDT
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion's parent company Sumitomo Dainippon Pharma Co., Ltd. Over the course of five years, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.
Streptococcus Pyogenes Infections Pipeline Review, H2 2015 - 6 Companies & 10 Drug Profiles
M2 - Mon Oct 05, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxmsnq/streptococcus) has announced the addition of the "Streptococcus Pyogenes Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Aureogen Biosciences, Inc. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Wellstat Vaccines, LLC Drug Profiles - BMY-28117 - HB-1345 - SM-295291 - SM-369926 - Small Molecules to Inhibit DHFR for Infectious Diseases - Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - streptococcus [serotype A] vaccine - streptococcus polysaccharide [serotype A] vaccine - streptococcus pyogenes vaccine - streptococcus pyogenes vaccine (30-valent) For more information visit http://www.researchandmarkets.com/research/px...eptococcus
GSK: 43.42 (-0.16)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 243.94 (+0.51), VRTX: 90.63 (-1.49), SRPT: 57.83 (-3.14), GSK: 43.42 (-0.16)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 81.48 (-0.55)
(0)
(0)Scroll down for more posts ▼